Literature DB >> 21474930

Association between prescription of conventional or atypical antipsychotic drugs and mortality in older persons with Alzheimer's disease.

Massimo Musicco1, Katie Palmer, Antonio Russo, Carlo Caltagirone, Fulvio Adorni, Carla Pettenati, Luigi Bisanti.   

Abstract

BACKGROUND/AIMS: To evaluate whether dementia patients prescribed antipsychotic drugs have a higher mortality compared to unexposed patients, and to investigate whether there are differences in mortality associated with exposure to conventional versus atypical antipsychotic drugs.
METHODS: Retrospective population cohort study with information gathered from the Italian Health Information System. All 4,369 residents of Milan (Italy) aged 60 years or older who were newly prescribed an antidementia drug (donepezil, rivastigmine or galantamine) from January 2002 to June 2008 were included. All new users of antipsychotic drugs in this cohort were categorized according to conventional (n = 156) or atypical (n = 806) drug exposure. The mortality risks of users of conventional or atypical antipsychotics compared to nonusers were evaluated with survival analysis, considering exposure to antipsychotic drugs as a time-dependent variable.
RESULTS: Mortality was increased two- and fivefold in users of atypical and conventional antipsychotics, respectively, with respect to nonusers.
CONCLUSIONS: Dementia patients prescribed antipsychotic drugs had a higher risk of death. This risk was highest for those prescribed conventional antipsychotics. At least part of the excess mortality may be due to the underlying neuropsychiatric symptoms that prompted the use of antipsychotics rather than a direct medication effect.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21474930     DOI: 10.1159/000326213

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  14 in total

Review 1.  Are the safety profiles of antipsychotic drugs used in dementia the same? An updated review of observational studies.

Authors:  Gianluca Trifiró; Janet Sultana; Edoardo Spina
Journal:  Drug Saf       Date:  2014-07       Impact factor: 5.606

Review 2.  Evidence and decision algorithm for the withdrawal of antipsychotic treatment in the elderly with dementia and neuropsychiatric symptoms.

Authors:  Marta Miarons; Christopher Cabib; Francisco Javier Barón; Laia Rofes
Journal:  Eur J Clin Pharmacol       Date:  2017-08-05       Impact factor: 2.953

Review 3.  Polypharmacy and inappropriate medication use in patients with dementia: an underresearched problem.

Authors:  Carole Parsons
Journal:  Ther Adv Drug Saf       Date:  2016-10-01

4.  Long-term use of pharmacological treatment in Alzheimer's disease: a retrospective cohort study in real-world clinical practice.

Authors:  G Lombardi; N Lombardi; A Bettiol; G Crescioli; C Ferrari; G Lucidi; C Polito; V Berti; V Bessi; S Bagnoli; B Nacmias; A Vannacci; S Sorbi
Journal:  Eur J Clin Pharmacol       Date:  2022-04-28       Impact factor: 2.953

5.  Predictors of mortality in atypical antipsychotic-treated community-dwelling elderly patients with behavioural and psychological symptoms of dementia: a prospective population-based cohort study from Italy.

Authors:  Concetta Rafaniello; Flavia Lombardo; Carmen Ferrajolo; Liberata Sportiello; Elisabetta Parretta; Ranieri Formica; Simona Potenza; Barbara Rinaldi; Antonio Irpino; Roberto Raschetti; Nicola Vanacore; Francesco Rossi; Annalisa Capuano
Journal:  Eur J Clin Pharmacol       Date:  2013-10-22       Impact factor: 2.953

6.  Atypical antipsychotic use in patients with dementia: managing safety concerns.

Authors:  Martin Steinberg; Constantine G Lyketsos
Journal:  Am J Psychiatry       Date:  2012-09       Impact factor: 18.112

7.  Treatment of dementia with lewy bodies.

Authors:  Brendon P Boot; Eric M McDade; Scott M McGinnis; Bradley F Boeve
Journal:  Curr Treat Options Neurol       Date:  2013-12       Impact factor: 3.598

8.  Factors that influence survival in a probable Alzheimer disease cohort.

Authors:  Susan D Rountree; Wenyaw Chan; Valory N Pavlik; Eveleen J Darby; Rachelle S Doody
Journal:  Alzheimers Res Ther       Date:  2012-05-15       Impact factor: 6.982

9.  Comprehensive treatment of dementia with Lewy bodies.

Authors:  Brendon P Boot
Journal:  Alzheimers Res Ther       Date:  2015-05-29       Impact factor: 6.982

10.  Donepezil and life expectancy in Alzheimer's disease: a retrospective analysis in the Tajiri Project.

Authors:  Kenichi Meguro; Mari Kasai; Kyoko Akanuma; Mitsue Meguro; Hiroshi Ishii; Satoshi Yamaguchi
Journal:  BMC Neurol       Date:  2014-04-11       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.